论文部分内容阅读
采用随机、双盲、平行对照方式,比较氟伐他汀40～80mg/d,(A组33例)和普伐他汀20～40mg/d,(B组35例)治疗原发性高胆固醇血症12周后的疗效和安全性。结果:A组服药12周后,血清TC、LDL-C、TC/HDL-C水平与O周时比较分别降低18.4％(P<0.001),24.7％(P<0.001)和11.7％(P<0.01);B组分别降低21.0％、31.5％和27.5％(P值均<0.001)。A组和B组服药12周时降低TC的总有效率分别为77.4％和82％。以上结果的组间比较均未达到统计学差别。加倍两种药物的治疗剂量均能提高降低TC的总有效率和显效率。两组治疗期间未发现明显不良反应,耐受性良好。
A randomized, double-blind, parallel-controlled trial comparing fluvastatin 40-80 mg / d (group A, 33 patients) and pravastatin 20-40 mg / d (group B, 35 patients) with primary hypercholesterolemia Efficacy and safety after 12 weeks. Results: The levels of TC, LDL-C and TC / HDL-C in group A decreased by 18.4% (P <0.001), 24.7% (P <0.001) and 11.7% 0.01). The B group decreased by 21.0%, 31.5% and 27.5% respectively (P <0.001). The total effective rate of lowering TC in group A and B at 12 weeks was 77.4% and 82%, respectively. The above results between groups did not reach statistical differences. Double the therapeutic dose of both drugs can increase the total effective rate of TC and significantly reduce the efficiency. No significant adverse reactions were found during the two groups and were well tolerated.